All Updates

All Updates

icon
Filter
Funding
AbCellera secures Canadian federal grant for CAD 701 million project
AI Drug Discovery
May 24, 2023
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Partnerships
Product updates
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
AI Drug Discovery

AI Drug Discovery

May 24, 2023

AbCellera secures Canadian federal grant for CAD 701 million project

Funding

  • Vancouver-based AI drug discovery company AbCellera Biologics, together with ​​the governments of Canada and British Columbia (BC), is co-investing in a CAD 701 million (USD 516 million) project over a period of eight years to extend the capacity of the company's manufacturing plant with the aim of expanding the drug development and manufacturing capacity of the region.

  • AbCellera will inject CAD 401 million (USD 295 million) into the project while the governments of Canada and BC will invest CAD 225 million (USD 166 million) and CAD 75 million (USD 55 million), respectively. 

  • The expanded facility, currently under construction, aims to expand the capabilities of Canada and BC in conducting research, discovering novel antibody therapies, and initiating preclinical development, all the way to conducting clinical trials. The facility is also expected to create more than 400 jobs.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.